teclistamab

Cecilia BrownMyeloma | November 22, 2022
Treatment with teclistamab, a T-cell–redirecting bispecific antibody, led to a “high rate of deep and durable...
Leah SherwoodMyeloma | November 16, 2022
Among 37 evaluable patients, the ORR was 78%, and 27 patients had a VGPR or better...
Advertisement
Advertisement
Advertisement
Advertisement